î
î
Genmab A/S
GMAB21.866USD
+0.086+0.39%
āđāļ§āļĨāļēāļāļģāļāļēāļĢāļāļĨāļēāļÂ ïžETïžāļĢāļēāļāļēāļĨāđāļēāļāđāļē 15 āļāļēāļāļĩ
1.39BāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
0.41P/E TTM
î
āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ Genmab A/S āļāļĢāļīāļĐāļąāļ
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
āļāđāļāļĄāļđāļĨāļāļĢāļīāļĐāļąāļî
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļGMAB
āļāļ·āđāļāļāļĢāļīāļĐāļąāļGenmab A/S
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 01, 2000
āļāļĩāļāļĩāđāļDr. Jan G.J. Van De Winkel, Ph.D.
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ2682
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļOct 01
āļāļĩāđāļāļĒāļđāđCarl Jacobsens Vej 30
āđāļĄāļ·āļāļVALBY
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđOMX Nordic Exchange Copenhagen A/S
āļāļĢāļ°āđāļāļĻDenmark
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ2500
āđāļāļĢāļĻāļąāļāļāđ4570202728
āđāļ§āđāļāđāļāļāđhttps://www.genmab.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļGMAB
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļOct 01, 2000
āļāļĩāļāļĩāđāļDr. Jan G.J. Van De Winkel, Ph.D.
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļî
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
Dr. Paolo Paoletti, M.D.
Dr. Paolo Paoletti, M.D.
Independent Director
Independent Director
--
--
Dr. Jan G.J. Van De Winkel, Ph.D.
Dr. Jan G.J. Van De Winkel, Ph.D.
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Ms. Mijke Zachariasse, Ph.D.
Ms. Mijke Zachariasse, Ph.D.
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Ms. Elizabeth A. O'farrell
Ms. Elizabeth A. O'farrell
Independent Director
Independent Director
--
--
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Dr. Tahamtan (Tahi) Ahmadi, M.D., Ph.D.
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
Executive Vice President, Chief Medical Officer, Head of Experimental Medicines
--
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
--
--
Ms. Pernille Lyngvold Erenbjerg
Ms. Pernille Lyngvold Erenbjerg
Independent Deputy Chairman of the Board
Independent Deputy Chairman of the Board
--
--
Mr. Christopher Cozic
Mr. Christopher Cozic
Executive Vice President, Chief People Officer
Executive Vice President, Chief People Officer
--
--
Mr. Martin Schultz
Mr. Martin Schultz
Non-Independent Director, Employee Elected
Non-Independent Director, Employee Elected
--
--
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Dr. Anders Gersel Pedersen, M.D., Ph.D.
Non-Independent Director
Non-Independent Director
--
--
āļŠāļąāļāļŠāđāļ§āļāļāļāļāļĢāļēāļĒāđāļāđ
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 6 āļ.āļ.
āļŠāļāļļāļĨāđāļāļīāļ: USDāļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļēāļāļīāļāļĒāđāļāļĩāđ 6 āļ.āļ.
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Royalties
589.00M
82.38%
Net product sales
75.00M
10.49%
Reimbursement income
23.00M
3.22%
Collaboration revenue
16.00M
2.24%
Milestone payments
12.00M
1.68%
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļāļēāļĄāļāļļāļĢāļāļīāļ
āļāļēāļĄāļ āļđāļĄāļīāļ āļēāļ
āļāļēāļĄāļāļļāļĢāļāļīāļUSD
āļāļ·āđāļ
āļĢāļēāļĒāđāļāđ
āļŠāļąāļāļŠāđāļ§āļ
Royalties
589.00M
82.38%
Net product sales
75.00M
10.49%
Reimbursement income
23.00M
3.22%
Collaboration revenue
16.00M
2.24%
Milestone payments
12.00M
1.68%
āļŠāļāļīāļāļīāļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 17 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 17 āļ.āļ.
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
AllianceBernstein L.P.
2.32%
Orbis Investment Management Ltd.
0.90%
Citadel Advisors LLC
0.70%
Two Sigma Investments, LP
0.61%
BlackRock Institutional Trust Company, N.A.
0.47%
Other
95.00%
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
AllianceBernstein L.P.
2.32%
Orbis Investment Management Ltd.
0.90%
Citadel Advisors LLC
0.70%
Two Sigma Investments, LP
0.61%
BlackRock Institutional Trust Company, N.A.
0.47%
Other
95.00%
āļāļĢāļ°āđāļ āļāļāļđāđāļāļ·āļāļŦāļļāđāļ
āļāļđāđāļāļ·āļāļŦāļļāđāļ
āļŠāļąāļāļŠāđāļ§āļ
Investment Advisor/Hedge Fund
4.27%
Investment Advisor
2.99%
Hedge Fund
2.45%
Research Firm
0.51%
Pension Fund
0.03%
Bank and Trust
0.02%
Venture Capital
0.01%
Other
89.73%
āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļî
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 1 āļ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāļāļąāļāļāļēāļĢāļāļĩāđ 1 āļ.āļ.
āļāđāļ§āļāđāļ§āļĨāļēāļāļēāļĢāļĢāļēāļĒāļāļēāļ
āļāļģāļāļ§āļāļŠāļāļēāļāļąāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
2025Q2
498
64.99M
10.26%
-6.57M
2025Q1
515
65.99M
10.42%
-5.32M
2024Q4
512
61.76M
9.33%
+621.44K
2024Q3
493
53.46M
8.41%
-4.14M
2024Q2
495
49.90M
7.86%
-6.30M
2024Q1
501
49.04M
7.53%
-7.16M
2023Q4
490
47.86M
7.32%
-6.37M
2023Q3
479
48.54M
7.43%
+204.98K
2023Q2
467
42.76M
6.55%
-5.77M
2023Q1
481
44.22M
6.78%
-6.32M
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
āļāļīāļāļāļĢāļĢāļĄāļāļđāđāļāļ·āļāļŦāļļāđāļî
āļāļ·āđāļ
āļŦāļļāđāļāļāļĩāđāļāļ·āļāļāļĢāļāļ
āļŠāļąāļāļŠāđāļ§āļ
āđāļāļĨāļĩāđāļĒāļ
āđāļāļĨāļĩāđāļĒāļ%
āļ§āļąāļāļāļĩāđ
AllianceBernstein L.P.
14.73M
2.32%
-210.07K
-1.41%
Mar 31, 2025
Orbis Investment Management Ltd.
5.71M
0.9%
+2.90M
+102.83%
Mar 31, 2025
Citadel Advisors LLC
4.43M
0.7%
+1.33M
+43.16%
Mar 31, 2025
Two Sigma Investments, LP
3.87M
0.61%
+513.60K
+15.29%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.95M
0.47%
-433.32K
-12.82%
Mar 31, 2025
Harding Loevner LP
2.88M
0.45%
+637.43K
+28.41%
Mar 31, 2025
Renaissance Technologies LLC
2.26M
0.36%
+336.20K
+17.45%
Mar 31, 2025
Marshall Wace LLP
2.18M
0.34%
+1.06M
+94.38%
Mar 31, 2025
Brandywine Global Investment Management, LLC
1.72M
0.27%
+97.63K
+6.03%
Mar 31, 2025
First Trust Advisors L.P.
1.71M
0.27%
+65.52K
+3.98%
Mar 31, 2025
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
ETF āļāļĩāđāđāļāļĩāđāļĒāļ§āļāđāļāļî
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 2 āļŠ.āļ.
āļāļąāļāđāļāļāđāļĄāļ·āđāļ: āļ§āļąāļāđāļŠāļēāļĢāđāļāļĩāđ 2 āļŠ.āļ.
āļāļ·āđāļ
āļŠāļąāļāļŠāđāļ§āļ
Tema Oncology ETF
3.66%
First Trust NYSE Arca Biotechnology Index Fund
3.45%
WisdomTree BioRevolution Fund
0.99%
iShares Biotechnology ETF
0.87%
First Trust NASDAQ BuyWrite Income ETF
0.2%
ProShares Ultra Nasdaq Biotechnology
0.1%
Invesco Nasdaq Biotechnology ETF
0.1%
Avantis International Equity ETF
0.07%
ActivePassive International Equity ETF
0.07%
Avantis International Large Cap Value ETF
0.05%
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Tema Oncology ETF
āļŠāļąāļāļŠāđāļ§āļ3.66%
First Trust NYSE Arca Biotechnology Index Fund
āļŠāļąāļāļŠāđāļ§āļ3.45%
WisdomTree BioRevolution Fund
āļŠāļąāļāļŠāđāļ§āļ0.99%
iShares Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.87%
First Trust NASDAQ BuyWrite Income ETF
āļŠāļąāļāļŠāđāļ§āļ0.2%
ProShares Ultra Nasdaq Biotechnology
āļŠāļąāļāļŠāđāļ§āļ0.1%
Invesco Nasdaq Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ0.1%
Avantis International Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.07%
ActivePassive International Equity ETF
āļŠāļąāļāļŠāđāļ§āļ0.07%
Avantis International Large Cap Value ETF
āļŠāļąāļāļŠāđāļ§āļ0.05%
āđāļāļīāļāļāļąāļāļāļĨî
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē
āļ§āļąāļāļāļĩāđ
āđāļāļīāļāļāļąāļāļāļĨ
āļ§āļąāļāļāļĩāđāļāļąāļāļāļķāļ
āļ§āļąāļāļāļĩāđāļāļģāļĢāļ°āđāļāļīāļ
āļ§āļąāļāļāļĩāđāđāļĄāđāđāļāđāļĢāļąāļāļŠāļīāļāļāļīāļāļąāļāļāļĨ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļāļēāļĢāđāļāđāļāļŦāļļāđāļî
āļ§āļąāļāļāļĩāđ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
āļ§āļąāļāļāļĩāđ
āļāļĢāļ°āđāļ āļ
āļāļąāļāļĢāļēāļŠāđāļ§āļ
āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ
